The potential of Metabolomics in assessing global compositional changes resulting from the application of CRISPR/Cas9 technologies (2022)
Attributed to:
21EBTA: Engineering plant cell factories for the production of biomedicines and their ingredients. (Acronym; Celfacto)
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.21203/rs.3.rs-2287743/v1
Publication URI: http://dx.doi.org/10.21203/rs.3.rs-2287743/v1
Type: Preprint